The Neuropathology Core serves a number of critical functions within the ADRC. It has and will continue to serve to prove the facilities, expertise and personnel to obtain brain specimens from well characterized elderly demented subjects (primarily suffering from Alzheimer's disease) as well as elderly control subjects. The Neuropathology Core provides 24 hour coverage by trained prosectors and has achieved an enviable record of short post-mortem intervals (mean post-mortem interval 282.9 + 162.6 minutes). To date, a total of 231 brains have been processed through the ADRC brain bank. Each brain specimen is subjected to a detailed dissection protocol which is specifically designed to provide optimally handled and preserved specimens for all of the researchers involved in the ADRC as well as other colleagues and collaborators involved in AD-related research. Each specimen undergoes a detailed neuropathology work-up in which the nature and extent of neuropathologic lesions present are evaluated and documented and a diagnostic neuropatholgic report is issued. The brain tissues obtained are actively used in the ADRC's research efforts and data obtained from these samples have resulted in many important scientific findings and a large number of publications. We have made a conscious decision to concentrate our efforts on obtaining brains from patients on whom detailed and reliable clinical information is available. Accordingly, we have been able to engage in studies which correlate the extent and distribution of certain neuropathologic lesions with clinical aspects of V disease as well as with neurochemical parameters. We have achieved an excellent autopsy record for longitudinally followed ADRC patients (68% of deaths of longitudinally followed ADRC patients have been autopsied). In order to achieve an even higher autopsy rate, we have introduced a procedure in which the next-of-kin is asked to declare an intent to consent to autopsy well in advance of the death of the patient. Due to the chronic nature of this disease, we anticipate that a large number of our longitudinally followed ADRC patients will die within the upcoming funding period and feel that our efforts in seeking intents to consent to autopsy will result in our obtaining many additional valuable specimens. The Neuropathology Core continues to play a central role in the success of this ADRC.

Agency
National Institute of Health (NIH)
Institute
National Institute on Aging (NIA)
Type
Specialized Center (P50)
Project #
5P50AG005138-12
Application #
3726299
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
12
Fiscal Year
1995
Total Cost
Indirect Cost
Name
Mount Sinai School of Medicine
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10029
Ki?emet-Piska?, Spomenka; Babi? Leko, Mirjana; Blažekovi?, Antonela et al. (2018) Evaluation of cerebrospinal fluid phosphorylated tau231 as a biomarker in the differential diagnosis of Alzheimer's disease and vascular dementia. CNS Neurosci Ther 24:734-740
Soleimani, Laili; Ravona-Springer, Ramit; Heymann, Anthony et al. (2018) Depression is more strongly associated with cognition in elderly women than men with type 2 diabetes. Int Psychogeriatr :1-5
Burke, Shanna L; Maramaldi, Peter; Cadet, Tamara et al. (2018) Decreasing hazards of Alzheimer's disease with the use of antidepressants: mitigating the risk of depression and apolipoprotein E. Int J Geriatr Psychiatry 33:200-211
Audrain, Mickael; Haure-Mirande, Jean-Vianney; Wang, Minghui et al. (2018) Integrative approach to sporadic Alzheimer's disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau. Mol Psychiatry :
Boban, Mirta; Babi? Leko, Mirjana; Miški?, Terezija et al. (2018) Human neuroblastoma SH-SY5Y cells treated with okadaic acid express phosphorylated high molecular weight tau-immunoreactive protein species. J Neurosci Methods :
Zhu, Carolyn W; Grossman, Hillel; Neugroschl, Judith et al. (2018) A randomized, double-blind, placebo-controlled trial of resveratrol with glucose and malate (RGM) to slow the progression of Alzheimer's disease: A pilot study. Alzheimers Dement (N Y) 4:609-616
Qian, Winnie; Fischer, Corinne E; Schweizer, Tom A et al. (2018) Association Between Psychosis Phenotype and APOE Genotype on the Clinical Profiles of Alzheimer's Disease. Curr Alzheimer Res 15:187-194
Davis, Jeremy J (2018) Performance validity in older adults: Observed versus predicted false positive rates in relation to number of tests administered. J Clin Exp Neuropsychol 40:1013-1021
Gallagher, Damien; Kiss, Alex; Lanctot, Krista et al. (2018) Depression and Risk of Alzheimer Dementia: A Longitudinal Analysis to Determine Predictors of Increased Risk among Older Adults with Depression. Am J Geriatr Psychiatry 26:819-827
Silverman, Jeremy M; Schmeidler, James (2018) Outcome age-based prediction of successful cognitive aging by total cholesterol. Alzheimers Dement 14:952-960

Showing the most recent 10 out of 555 publications